Universe Pharmaceuticals (UPC) Common Equity: 2020-2024
- Universe Pharmaceuticals' Common Equity rose 62.68% to $45.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $45.5 million, marking a year-over-year increase of 62.68%. This contributed to the annual value of $45.5 million for FY2024, which is 62.68% up from last year.
- Per Universe Pharmaceuticals' latest filing, its Common Equity stood at $45.5 million for Q3 2024, which was up 70.14% from $26.7 million recorded in Q1 2024.
- Over the past 5 years, Universe Pharmaceuticals' Common Equity peaked at $61.2 million during Q1 2022, and registered a low of $20.8 million during Q3 2020.
- Its 3-year average for Common Equity is $40.6 million, with a median of $40.4 million in 2022.
- Its Common Equity has fluctuated over the past 5 years, first soared by 125.89% in 2021, then slumped by 43.25% in 2024.
- Universe Pharmaceuticals' Common Equity (Quarterly) stood at $20.8 million in 2020, then spiked by 125.89% to $47.0 million in 2021, then dropped by 24.82% to $35.3 million in 2022, then decreased by 20.83% to $28.0 million in 2023, then soared by 62.68% to $45.5 million in 2024.
- Its Common Equity was $45.5 million in Q3 2024, compared to $26.7 million in Q1 2024 and $28.0 million in Q3 2023.
